SSA
SGMT icon

Schonfeld Strategic Advisors’s Sagimet Biosciences SGMT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-523,774
Closed -$3.59M – 2534
2025
Q3 		$3.59M Buy
523,774
+430,644
+462% +$3.49M 0.02% 744
2025
Q2 		$710K Buy
+93,130
New +$393K ﹤0.01% 1433
2025
Q1 		– Sell
-39,452
Closed -$178K – 2467
2024
Q4 		$178K Sell
39,452
-68,048
-63% -$345K ﹤0.01% 1779
2024
Q3 		$298K Sell
107,500
-79,800
-43% -$246K ﹤0.01% 1654
2024
Q2 		$641K Sell
187,300
-106,100
-36% -$487K ﹤0.01% 1383
2024
Q1 		$1.59M Buy
+293,400
New +$2.11M 0.01% 1062

Other funds holding SGMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's SGMT Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Sagimet Biosciences (SGMT) in Q4 2025, closing a stake of 523,774 shares — an estimated $3.59M sold.

Schonfeld Strategic Advisors first reported a position in SGMT in Q1 2024 and held it in 6 quarters. The position peaked at $3.59M in Q3 2025. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Sagimet Biosciences position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 523,774 Sagimet Biosciences shares in Q4 2025, an estimated $3.59M.
  • Schonfeld Strategic Advisors first reported a position in Sagimet Biosciences in Q1 2024 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's Sagimet Biosciences position peaked at $3.59M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.